AR034132A1 - Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica - Google Patents
Analogos de somatostatina, un proceso para su produccion y composicion farmaceuticaInfo
- Publication number
- AR034132A1 AR034132A1 ARP010103642A ARP010103642A AR034132A1 AR 034132 A1 AR034132 A1 AR 034132A1 AR P010103642 A ARP010103642 A AR P010103642A AR P010103642 A ARP010103642 A AR P010103642A AR 034132 A1 AR034132 A1 AR 034132A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- insulin
- production
- pharmaceutical composition
- somatostatine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Un análogo de somatostatina, que comprende compuesto de la fórmula (1) estando uno de los grupos amino opcionalmente en forma protegida, o una salo complejo del mismo; un proceso para su producción y una composición farmacéutica que es para utilizarse en combinación con un agente inmunosupresor, un agente anti-inflamatorio, un agente modulador de receptor de secretagogo de hormona de crecimiento, un antagonista del receptor de hormona de crecimiento, un secretagogo de insulina, un potenciador de la secreción de insulina, un sensibilizante de insulina, una dosis baja de insulina, un agente que tenga efectos anti-angiogenéticos, o un agente quimioterapéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0018891.2A GB0018891D0 (en) | 2000-08-01 | 2000-08-01 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034132A1 true AR034132A1 (es) | 2004-02-04 |
Family
ID=9896782
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010103642A AR034132A1 (es) | 2000-08-01 | 2001-07-30 | Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica |
Country Status (36)
Country | Link |
---|---|
US (5) | US7473761B2 (es) |
EP (1) | EP1307486B1 (es) |
JP (1) | JP3829118B2 (es) |
KR (2) | KR100799394B1 (es) |
CN (1) | CN1267451C (es) |
AR (1) | AR034132A1 (es) |
AT (1) | ATE393782T1 (es) |
AU (2) | AU8977801A (es) |
BE (1) | BE2012C026I2 (es) |
BR (1) | BRPI0112859B8 (es) |
CA (1) | CA2416293C (es) |
CY (2) | CY1108547T1 (es) |
CZ (1) | CZ302461B6 (es) |
DE (1) | DE60133823T2 (es) |
DK (1) | DK1307486T3 (es) |
EC (1) | ECSP034456A (es) |
ES (1) | ES2305104T3 (es) |
FR (1) | FR12C0041I2 (es) |
GB (1) | GB0018891D0 (es) |
HK (1) | HK1057051A1 (es) |
HU (1) | HU227812B1 (es) |
IL (2) | IL153920A0 (es) |
LU (1) | LU92024I2 (es) |
MX (1) | MXPA03000991A (es) |
MY (1) | MY138074A (es) |
NO (2) | NO331093B1 (es) |
NZ (1) | NZ523836A (es) |
PE (1) | PE20020176A1 (es) |
PL (1) | PL204161B1 (es) |
PT (1) | PT1307486E (es) |
RU (1) | RU2287533C2 (es) |
SI (1) | SI1307486T1 (es) |
SK (1) | SK287798B6 (es) |
TW (1) | TWI282341B (es) |
WO (1) | WO2002010192A2 (es) |
ZA (1) | ZA200300406B (es) |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
AU2002359359A1 (en) | 2001-12-28 | 2003-07-24 | Somatocor Pharmaceuticals, Inc. | Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands |
WO2004052817A1 (en) * | 2002-12-12 | 2004-06-24 | Novartis Ag | Process for peptide synthesis of peptides containing a 4-hydroxy-proline substructure |
GB0229020D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic compounds |
GB0300095D0 (en) * | 2003-01-03 | 2003-02-05 | Novartis Ag | Organic compounds |
GB0314695D0 (en) * | 2003-06-24 | 2003-07-30 | Novartis Ag | Organic compounds |
PE20050285A1 (es) * | 2003-06-24 | 2005-06-09 | Novartis Ag | Composicion farmaceutica que comprende analogos ciclicos de somatostatina |
GB0318682D0 (en) * | 2003-08-08 | 2003-09-10 | Novartis Ag | Organic compounds |
EP1522311A1 (fr) | 2003-10-10 | 2005-04-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée |
MY158342A (en) | 2003-11-14 | 2016-09-30 | Novartis Ag | Pharmaceutical composition |
GB0412866D0 (en) * | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
GB0428151D0 (en) | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
GB0602639D0 (en) | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
RU2008151727A (ru) * | 2006-06-08 | 2010-07-20 | Новартис АГ (CH) | Комбинация аналогов соматостатина с антагонистом рецептора дофамина или рецептора гормона роста |
US7697338B2 (en) * | 2006-11-16 | 2010-04-13 | Sandisk Corporation | Systems for controlled boosting in non-volatile memory soft programming |
CN101553728B (zh) * | 2006-11-28 | 2013-02-06 | 香港大学 | 颗粒体蛋白-上皮素前体(gep)抗体用于检测和抑制肝细胞癌(hcc)的用途 |
EP1941902A1 (en) * | 2007-01-02 | 2008-07-09 | Novartis AG | Use of Somatostatin analogs in cluster headache |
PT2118123E (pt) | 2007-01-31 | 2016-02-10 | Harvard College | Péptidos de p53 estabilizados e suas utilizações |
EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
PE20090387A1 (es) | 2007-05-24 | 2009-04-28 | Novartis Ag | Formulacion de pasireotida |
WO2009009035A1 (en) * | 2007-07-06 | 2009-01-15 | Ipsen Pharma S.A.S. | Somatostatin analog and uses thereof |
GB0719818D0 (en) * | 2007-10-11 | 2007-11-21 | Asterion Ltd | Growth hormone fusion polypeptides |
PL2224947T3 (pl) * | 2007-11-28 | 2015-08-31 | Novartis Ag | Zastosowanie analogów somatostatyny w leczeniu oponiaka |
EP2067786A1 (en) | 2007-12-07 | 2009-06-10 | ITALFARMACO S.p.A. | Novel non selective analogs of somatostatin |
ES2431573T3 (es) | 2007-12-03 | 2013-11-27 | Italfarmaco S.P.A. | Nuevos análogos no selectivos de somatostatina |
US20090325863A1 (en) * | 2008-06-13 | 2009-12-31 | Kleinberg David L | Somatostatin analogs and IGF-I inhibition for breast cancer prevention |
US9314508B2 (en) * | 2008-07-08 | 2016-04-19 | Novartis Ag | Use of somatostatin analogs in control of hypoglycemia |
EP2172189A1 (en) | 2008-10-01 | 2010-04-07 | Novartis AG | Pharmaceutical Compositions |
EP2213307A1 (en) | 2009-02-03 | 2010-08-04 | Novartis AG | Injectable depot formulations |
SI2343982T1 (sl) | 2008-09-17 | 2017-08-31 | Chiasma Inc. | Farmacevtski sestavki in metode povezane z dostavo |
UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
PT2603600T (pt) | 2010-08-13 | 2019-02-27 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos |
WO2012074559A2 (en) | 2010-12-02 | 2012-06-07 | New York University | Treatment of non-proliferative cystic disease |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
US20130266590A1 (en) | 2010-12-13 | 2013-10-10 | Novartis Ag | Dimeric iap inhibitors |
US20130035054A1 (en) * | 2011-07-14 | 2013-02-07 | Faceon Mobile | Phone with multi-portal access for display during incoming and outgoing call |
WO2013019923A2 (en) | 2011-08-02 | 2013-02-07 | New York University | Methods for detecting progenitor cells and uses thereof |
KR20140069235A (ko) | 2011-09-27 | 2014-06-09 | 노파르티스 아게 | 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
CA2852468A1 (en) | 2011-10-18 | 2013-04-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
KR20140098242A (ko) | 2011-12-05 | 2014-08-07 | 노파르티스 아게 | 안드로겐 수용체 길항제로서의 시클릭 우레아 유도체 |
CN104105479B (zh) | 2011-12-05 | 2018-04-10 | 卡穆鲁斯公司 | 鲁棒性控释制剂 |
CN104302768A (zh) | 2012-01-09 | 2015-01-21 | 诺华股份有限公司 | 治疗β-联蛋白相关疾病的有机组合物 |
US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
RU2017145921A (ru) | 2012-02-15 | 2019-02-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы |
NZ702028A (en) * | 2012-05-25 | 2016-07-29 | Camurus Ab | Somatostatin receptor agonist formulations |
TWI633887B (zh) * | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及/或治療多囊性腎臟病之藥物 |
BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
US9480759B2 (en) | 2012-11-21 | 2016-11-01 | Serene, Llc | Tin-117m somatostatin receptor binding compounds and methods |
AU2014219283C1 (en) | 2013-02-19 | 2016-10-27 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
EA028033B1 (ru) | 2013-03-14 | 2017-09-29 | Новартис Аг | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантного idh |
WO2014141153A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
WO2014147586A1 (en) | 2013-03-22 | 2014-09-25 | Novartis Ag | 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh |
CN103467575B (zh) * | 2013-08-22 | 2016-03-02 | 深圳翰宇药业股份有限公司 | 一种帕西瑞肽的制备方法 |
CN103641894B (zh) * | 2013-12-06 | 2015-10-28 | 深圳翰宇药业股份有限公司 | 一种治疗库欣病的多肽药物的制备方法 |
WO2015092634A1 (en) | 2013-12-16 | 2015-06-25 | Novartis Ag | 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders |
MX2016008070A (es) | 2013-12-19 | 2017-05-12 | Novartis Ag | Sistemas de administracion de farmaco. |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
JP6473457B2 (ja) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物 |
JP6523303B2 (ja) | 2014-01-17 | 2019-05-29 | ノバルティス アーゲー | Shp2の活性を阻害するための1−ピリダジン/トリアジン−3−イル−ピペラジン/ピペリジン/ピロリジン誘導体およびその組成物 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR20220126813A (ko) | 2014-03-14 | 2022-09-16 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
KR20170005492A (ko) | 2014-05-28 | 2017-01-13 | 아이데닉스 파마슈티칼스 엘엘씨 | 암의 치료를 위한 뉴클레오시드 유도체 |
SG11201702223UA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
WO2016089833A1 (en) | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
EP3226688B1 (en) | 2014-12-05 | 2020-07-01 | Merck Sharp & Dohme Corp. | Tricyclic compounds as inhibitors of mutant idh enzymes |
EP3226689B1 (en) | 2014-12-05 | 2020-01-15 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
AU2015360485B2 (en) | 2014-12-10 | 2020-06-25 | Amryt Endo, Inc. | Oral octreotide administered in combination with other therapeutic agents |
EP3233899B1 (en) * | 2014-12-19 | 2020-06-24 | Auro Peptides LTD | A process for the preparation of pasireotide |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
WO2016126830A1 (en) | 2015-02-03 | 2016-08-11 | Chiasma Inc. | Method of treating diseases |
JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
BR112017019738A2 (pt) | 2015-03-20 | 2018-05-29 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
US10730911B2 (en) | 2015-04-08 | 2020-08-04 | Universitat Zurich | Backbone-cyclized peptidomimetics with GLP-1R modulating activity |
EP3303361A1 (en) | 2015-05-27 | 2018-04-11 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of cancer |
JP6878316B2 (ja) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Shp2の活性を阻害するための化合物および組成物 |
CN112625028A (zh) | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
US10556924B2 (en) | 2015-06-22 | 2020-02-11 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the preparation of pasireotide |
GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
PL3317301T3 (pl) | 2015-07-29 | 2021-11-15 | Novartis Ag | Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3 |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
CR20180101A (es) | 2015-08-13 | 2018-04-12 | Merck Sharp & Dohme | Compuestos di-nucleóticos cíclicos como agonistas de sting |
RS63125B1 (sr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Antitela koja se specifično vezuju za pd-1 i njihova upotreba |
US10538497B2 (en) | 2015-12-15 | 2020-01-21 | Merck Sharp & Dohme Corp. | Compounds as indoleamine 2,3-dioxygenase inhibitors |
AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
ES2849560T3 (es) | 2016-05-04 | 2021-08-19 | Genoscience Pharma Sas | Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas |
MX2018015625A (es) | 2016-06-14 | 2019-03-06 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
AR109788A1 (es) | 2016-10-04 | 2019-01-23 | Merck Sharp & Dohme | Compuestos de benzo[b]tiofeno como agonistas de sting |
EP3541825A1 (en) | 2016-11-21 | 2019-09-25 | Idenix Pharmaceuticals LLC. | Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases |
US11021511B2 (en) | 2017-01-27 | 2021-06-01 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
US11492367B2 (en) | 2017-01-27 | 2022-11-08 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
WO2018208667A1 (en) | 2017-05-12 | 2018-11-15 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
EP3661498A4 (en) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme Corp. | BENZO [B] THIOPHEN STING ANTAGONISTS FOR CANCER TREATMENT |
US11312772B2 (en) | 2017-08-04 | 2022-04-26 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment |
CN111201223A (zh) | 2017-09-11 | 2020-05-26 | 克鲁松制药公司 | SHP2的八氢环戊二烯并[c]吡咯别构抑制剂 |
WO2019067332A1 (en) | 2017-09-27 | 2019-04-04 | Merck Sharp & Dohme Corp. | COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST |
WO2019078968A2 (en) * | 2017-10-18 | 2019-04-25 | Angex Pharmaceutical, Inc. | CYCLIC COMPOUNDS AS IMMUNOMODULATORS |
EP3703692A4 (en) | 2017-11-01 | 2021-04-28 | Merck Sharp & Dohme Corp. | NEW SUBSTITUTED TETRAHYDROQUINOLINE COMPOUNDS USED AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS |
US10647705B2 (en) | 2017-11-14 | 2020-05-12 | Merck Sharp & Dohme Corp. | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
US11498904B2 (en) | 2017-11-14 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
AU2018386222B2 (en) | 2017-12-15 | 2023-04-20 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
CA3095646A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
EP3810116B1 (en) | 2018-05-31 | 2023-11-15 | Merck Sharp & Dohme LLC | Novel substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors |
US10596278B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
US10596276B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
CN112996795A (zh) | 2018-09-18 | 2021-06-18 | 尼坎医疗公司 | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 |
JP2022502496A (ja) | 2018-09-25 | 2022-01-11 | ブラック ダイアモンド セラピューティクス,インコーポレイティド | チロシンキナーゼ阻害剤組成物、作製方法、および使用方法 |
MX2021003517A (es) | 2018-09-25 | 2021-08-16 | Black Diamond Therapeutics Inc | Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso. |
BR112021005606A2 (pt) | 2018-09-29 | 2021-06-22 | Novartis Ag | processo de produção de um composto para inibir a atividade de shp2 |
EP3873464A4 (en) | 2018-11-01 | 2022-06-08 | Merck Sharp & Dohme Corp. | NOVEL SUBSTITUTED PYRAZOLE COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
WO2020096871A1 (en) | 2018-11-06 | 2020-05-14 | Merck Sharp & Dohme Corp. | Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors |
US20230008022A1 (en) | 2018-11-28 | 2023-01-12 | Merck Sharp & Dohme Corp. | Novel substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
US20220177465A1 (en) | 2019-04-04 | 2022-06-09 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes |
WO2020260547A1 (en) | 2019-06-27 | 2020-12-30 | Rigontec Gmbh | Design method for optimized rig-i ligands |
TW202120500A (zh) | 2019-08-02 | 2021-06-01 | 美商梅爾莎納醫療公司 | 干擾素基因刺激蛋白(sting)激動劑化合物及用途 |
EP4013749A1 (en) | 2019-08-15 | 2022-06-22 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
AU2020373913B2 (en) | 2019-10-28 | 2024-04-18 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof |
WO2021113679A1 (en) | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
WO2021195206A1 (en) | 2020-03-24 | 2021-09-30 | Black Diamond Therapeutics, Inc. | Polymorphic forms and related uses |
EP4146644A1 (en) | 2020-05-06 | 2023-03-15 | Merck Sharp & Dohme LLC | Il4i1 inhibitors and methods of use |
AU2021409561A1 (en) | 2020-12-22 | 2023-07-06 | Nikang Therapeutics, Inc. | Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway |
US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
EP4277901A1 (en) | 2021-01-13 | 2023-11-22 | Monte Rosa Therapeutics, Inc. | Isoindolinone compounds |
WO2022170052A1 (en) | 2021-02-05 | 2022-08-11 | Black Diamond Therapeutics, Inc. | Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof |
WO2022219407A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
WO2022219412A1 (en) | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
WO2022227015A1 (en) | 2021-04-30 | 2022-11-03 | Merck Sharp & Dohme Corp. | Il4i1 inhibitors and methods of use |
TW202317589A (zh) | 2021-07-14 | 2023-05-01 | 美商尼坎醫療公司 | 作為kras抑制劑的伸烷基衍生物 |
US20230303509A1 (en) | 2022-03-28 | 2023-09-28 | Nikang Therapeutics, Inc. | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors |
WO2023240024A1 (en) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
WO2024047112A1 (en) * | 2022-08-30 | 2024-03-07 | Somtheranostics Sarl | Halogenated somatostatin analogs with multiple somatostatin receptor subtype selectivity |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3863008A (en) | 1973-06-11 | 1975-01-28 | American Home Prod | Somatostatin as stimulant of luteinizing hormone secretion |
NZ195303A (en) | 1979-10-31 | 1984-10-19 | Merck & Co Inc | Cyclic hexapeptide somatostatin analogues,and pharmaceutical compositions |
US4292972A (en) | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
US4612386A (en) * | 1980-09-16 | 1986-09-16 | The Dow Chemical Company | Process for making esters |
US4505897A (en) | 1983-04-18 | 1985-03-19 | The Administrators Of The Tulane Educational Fund | Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith |
US4612366A (en) | 1985-06-17 | 1986-09-16 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
CA2012115C (en) | 1989-03-15 | 2001-07-03 | Biomeasure, Inc. | Iodinated somatostatins |
JP2882679B2 (ja) | 1989-04-26 | 1999-04-12 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | 線状ソマトスタチン類似体 |
US5620675A (en) | 1992-06-23 | 1997-04-15 | Diatech, Inc. | Radioactive peptides |
US5716596A (en) | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
ATE199089T1 (de) | 1993-06-23 | 2001-02-15 | Diatide Inc | Radiomarkierte somatostatin derivate zur abbildung und zur therapeutischen verwendung |
JP3618750B2 (ja) | 1993-08-09 | 2005-02-09 | ソシエテ ドゥ コンセイユ ドゥ ルシェルシュ エ ダプリカシオン サイエンティフィク,エス.アー.エス. | 治療効果のあるペプチド誘導体 |
US5770687A (en) | 1995-06-07 | 1998-06-23 | Peptor Limited | Comformationally constrained backbone cyclized somatostatin analogs |
MY147327A (en) * | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
IT1277391B1 (it) | 1995-07-28 | 1997-11-10 | Romano Deghenghi | Peptidi ciclici analoghi della somatostatina ad attivita' inibitrice dell'ormone della crescita |
JP2001525793A (ja) | 1996-05-14 | 2001-12-11 | ノボ ノルディスク アクティーゼルスカブ | ソマトスタチンの作動因子及び拮抗因子 |
US6355613B1 (en) | 1996-07-31 | 2002-03-12 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
CA2246791A1 (en) | 1998-09-01 | 2000-03-01 | Alison Buchan | Treatment of endothelium with somatostatin analogues |
GB0018891D0 (en) * | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
-
2000
- 2000-08-01 GB GBGB0018891.2A patent/GB0018891D0/en not_active Ceased
-
2001
- 2001-07-26 TW TW090118314A patent/TWI282341B/zh active
- 2001-07-26 PE PE2001000760A patent/PE20020176A1/es active IP Right Grant
- 2001-07-30 BR BRPI0112859A patent/BRPI0112859B8/pt not_active IP Right Cessation
- 2001-07-30 CA CA2416293A patent/CA2416293C/en not_active Expired - Lifetime
- 2001-07-30 WO PCT/EP2001/008824 patent/WO2002010192A2/en active IP Right Grant
- 2001-07-30 MX MXPA03000991A patent/MXPA03000991A/es active IP Right Grant
- 2001-07-30 AU AU8977801A patent/AU8977801A/xx active Pending
- 2001-07-30 HU HU0300684A patent/HU227812B1/hu active Protection Beyond IP Right Term
- 2001-07-30 PT PT01969555T patent/PT1307486E/pt unknown
- 2001-07-30 MY MYPI20013578A patent/MY138074A/en unknown
- 2001-07-30 EP EP01969555A patent/EP1307486B1/en not_active Expired - Lifetime
- 2001-07-30 SK SK121-2003A patent/SK287798B6/sk not_active IP Right Cessation
- 2001-07-30 JP JP2002515921A patent/JP3829118B2/ja not_active Expired - Lifetime
- 2001-07-30 CZ CZ20030288A patent/CZ302461B6/cs unknown
- 2001-07-30 DK DK01969555T patent/DK1307486T3/da active
- 2001-07-30 KR KR1020067005526A patent/KR100799394B1/ko active IP Right Grant
- 2001-07-30 AR ARP010103642A patent/AR034132A1/es active IP Right Grant
- 2001-07-30 DE DE60133823T patent/DE60133823T2/de not_active Expired - Lifetime
- 2001-07-30 US US10/343,288 patent/US7473761B2/en active Active
- 2001-07-30 KR KR10-2003-7001435A patent/KR20030033008A/ko not_active Application Discontinuation
- 2001-07-30 CN CNB018136869A patent/CN1267451C/zh not_active Expired - Lifetime
- 2001-07-30 AT AT01969555T patent/ATE393782T1/de active
- 2001-07-30 IL IL15392001A patent/IL153920A0/xx unknown
- 2001-07-30 RU RU2003105817/04A patent/RU2287533C2/ru active Protection Beyond IP Right Term
- 2001-07-30 ES ES01969555T patent/ES2305104T3/es not_active Expired - Lifetime
- 2001-07-30 NZ NZ523836A patent/NZ523836A/en not_active IP Right Cessation
- 2001-07-30 PL PL358718A patent/PL204161B1/pl unknown
- 2001-07-30 SI SI200130836T patent/SI1307486T1/sl unknown
- 2001-07-30 AU AU2001289778A patent/AU2001289778B2/en active Active
-
2003
- 2003-01-13 IL IL153920A patent/IL153920A/en active Protection Beyond IP Right Term
- 2003-01-15 ZA ZA200300406A patent/ZA200300406B/xx unknown
- 2003-01-29 EC EC2003004456A patent/ECSP034456A/es unknown
- 2003-01-30 NO NO20030484A patent/NO331093B1/no not_active IP Right Cessation
- 2003-11-07 HK HK03108087A patent/HK1057051A1/xx not_active IP Right Cessation
-
2008
- 2008-07-29 CY CY20081100789T patent/CY1108547T1/el unknown
- 2008-11-05 US US12/265,135 patent/US7939625B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 US US13/048,932 patent/US8822637B2/en not_active Expired - Lifetime
- 2011-03-16 US US13/048,935 patent/US9035021B2/en not_active Expired - Lifetime
-
2012
- 2012-06-20 LU LU92024C patent/LU92024I2/fr unknown
- 2012-06-21 BE BE2012C026C patent/BE2012C026I2/fr unknown
- 2012-06-26 FR FR12C0041C patent/FR12C0041I2/fr active Active
- 2012-06-29 NO NO2012012C patent/NO2012012I2/no not_active IP Right Cessation
- 2012-06-29 CY CY2012018C patent/CY2012018I1/el unknown
-
2015
- 2015-04-08 US US14/681,226 patent/US20150218223A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034132A1 (es) | Analogos de somatostatina, un proceso para su produccion y composicion farmaceutica | |
MY174339A (en) | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions | |
HUP9902121A2 (hu) | Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
AR018526A1 (es) | COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED | |
ES2065701T3 (es) | Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas. | |
NO965012L (no) | Farmasöytisk preparat som omfatter glukagon | |
AR036813A1 (es) | Composiciones farmaceuticas | |
AR006598A1 (es) | "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación" | |
SE8305485D0 (sv) | Galenic compositions comprising calcitonin and their use | |
AR031067A1 (es) | Un sachet; una tableta y un polvo efervescente de administracion oral para prevenir y tratar disfunciones sexuales y el uso de l-arginina y/o yohimbina y/o una sal farmaceuticamente aceptable de la misma. | |
LV10954A (lv) | Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija | |
ATE219061T1 (de) | Huperzin a analoge verbindungen | |
EE03180B1 (et) | Bombesiini antagonistpeptiidid, farmatseutiline kompositsioon ja kasutamine | |
PT97395A (pt) | Processo para a preparacao de 2,9-di-substituidas-4h-pirido{1,2-a}-pirimidin-4-onas e de composicoes farmaceuticas que os contem | |
DE602004015725D1 (de) | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors | |
MY135646A (en) | Indolyl derivatives | |
ATE388695T1 (de) | Pharmazeutische zusammensetzung enthaltend ein benzimidazol-derivat gemischt mit mikrokristalliner cellulose | |
ES2083708T3 (es) | Nuevas piperazinilalcoil-3 dihidro-2,3,4h-benzoxazina-1,3 onas-4 sustituidas, su preparacion y su aplicacion en terapeutica. | |
ES2171459T3 (es) | Polvo para administracion nasal de farmaco peptidico o proteinaceo. | |
AR035553A1 (es) | Formas cristalinas de melagatran, proceso para su produccion, formulacion farmaceutica, y uso de este compuesto en la elaboracion de medicamentos. | |
JPS5781409A (en) | External plaster | |
UY26211A1 (es) | Polimorfos de un diclorhidrato cristalino de azobiciclo (2.2.2)oct-3-ilamina y sus composiciones farmaceuticas | |
UY26176A1 (es) | Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas. | |
AR012602A1 (es) | Derivados de amidina, formulacion farmaceutica, uso de dichos derivados para la fabricacion de medicamentos y proceso para la preparacion de dichosderivados | |
DE3264906D1 (en) | Aminoglycoside derivatives, processes for their production, pharmaceutical compositions containing them and such derivatives for use as pharmaceuticals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |